Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection

9 Mar 2023

Abstract excerpt

The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing pandemic, underscoring the need for a dynamic platform for the rapid development of pan-viral variant therapeutics. Oligonucleotide therapeutics are enhancing the treatment of numerous diseases with unprecedented potency, duration of effect, and safety. Through the systematic screening of hundreds of oligonucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA Interference and Gene Delivery
Share to Advanced biosensing and bioanalysis techniques
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36893269
DOI: 10.1073/pnas.2219523120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infectionPMID 36893269Read ↗

An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.Semantic proximity Read ↗

In Silico and In Vitro development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2Semantic proximity Read ↗

In Silico and In Vitro Development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2Semantic proximity Read ↗

Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIVSemantic proximity Read ↗

Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxisSemantic proximity Read ↗

Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2Semantic proximity Read ↗

Prospects for RNAi Therapy of COVID-19Semantic proximity Read ↗

An intranasal ASO therapeutic targeting SARS-CoV-2Semantic proximity Read ↗

Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19Semantic proximity Read ↗

Design and Delivery of Therapeutic siRNAs: Application to MERS-CoronavirusSemantic proximity Read ↗

Biochemistry-informed design selects potent siRNAs against SARS-CoV-2Semantic proximity Read ↗

Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based deliverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.